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EDITORIAL
that achieves insulin-independent, constant
normoglycemic state and avoidance of  hypoglyc-
emic episodes is the replacement of  a patient’s is-
let of Langerhans either by pancreas transplanta-
tion or by isolated islet transplantation. The cost
of this benefit, however, is the need for immuno-
supressive treatment of the recipient with all its
potential risks.
Currently, only vascularized pancreas trans-
plantation can re-establish long-term normoglyc-
emia however this has been associate with signifi-
cant morbidity and mortality. Approximately
25.000 patients worldwide underwent this proce-
dure and it has been shown to improve quality of
life and even reverse some secondary complica-
tions of  diabetes.4 Simultaneous pancreas and kid-
ney transplantation are presently considered the
standard of care for selected patients with type I
diabetes with end-stage renal failure.5
Diabetes is a major burden tohealthcare economies despite the
use of exogenous insulin injec-
tions. Type I diabetes mellitus is a chronic meta-
bolic disorder that currently afflicts 5 million indi-
viduals in the world. It results from auto-immune
mediated destruction of  insulin secreting beta cells
in islet of  Langerhans of  the pancreas.1 Long-term
studies strongly suggest that tight control of  blood
glucose achieved by conventional or intensive in-
sulin treatment, self blood glucose monitoring, and
patient education can significantly prevent devel-
oping and retard the progression of chronic com-
plications of this disease.2 On the other hand, the
cost of this benefit was a threefold increase in the
number of severe hypoglycemic episodes, a sig-
nificant increase of body weight and dietary and
other lifestyle restrictions affecting the quality of
life.3 The only treatment for Type I diabetes mellitus
Human islet transplantation
Transplante de ilhotas em humanos
Eleazar Chaib
Associate Professor, Division of  Liver Transplantation and Transplantation Surgery, LIM 37, Department of Gastroenterology,
University of Sao Paulo School of Medicine, Sao Paulo, Brazil. eleazarchaib@yahoo.co.uk
2Medicina (Ribeirão Preto) 2014;47(1):1-4
http://revista.fmrp.usp.br/Chaib E. Human islet transplantation
Islet transplantation is an attractive treat-
ment for type I diabetic patients, the procedure
itself does not require general anesthesia or major
surgery. It is considered a minimally invasive pro-
cedure, in which islet can be perfused percutane-
ously into the liver via the portal vein in local
anesthesia  and does not require hospitalization.6
After the initial experience with poor results with
islet transplantation in the early 1990s, a detailed
review of cumulative world experience in clinical
islet transplantation clearly highlighted several fac-
tors as being causative for failure in the majority
of cases transplanted until 19997: 1. inadequate
islet transplant mass; 2. inadequate islet potency;
3. inadequate prophylaxis against allograft re-
jection or autoimmunity; and 4. routine use of
toxic diabetogenic immunosuppression after
transplantation.
A new protocol implemented in Edmonton
(1999) was designed to systematically address each
of  the above limitations. Shapiro et al (2000),
University of Alberta in Edmonton, Canada, re-
ported successful reversal of diabetes by pancre-
atic islet transplantation in seven consecutives
patients.8 The major novel approach was to trans-
plant an adequate islet mass through repeated is-
let implantations on a corticosteroid-free immu-
nosuppressive regimen. Its include harvesting the
pancreas before multiorgan retrieval, avoidance of
prolonged cold storage of the pancreas (<8 h),
avoidance of  animal serum products during isola-
tion and a target mass of at least 11.000 islet
equivalent (IEQ)/kg of recipient  bodyweight,
Table 1
Eleven institutions with ≥ 20 adult islet allografs in
type 1 diabetic patients 1990-2005
Institution Year of TX Nº of cases
Edmonton 1991-2005 99
Giessen 1992-2005 93
Milan 1991-2005 79
Brussels (Free Univ.) 1994-2005 74
Minneapolis 1991-2005 66
Miami 1991-2005 55
Geneva 1994-2005 39
GRAGIL/Geneva 1999-2005 34
Nordic Network/Uppsala 2001-2005 32
Philadelphia 2001-2005 30
Brussels (Louvain) 2000-2005 24
591a
Data from the International Islet Transplant Registry (ITR),
Giessen / Germany
a 66% of all adult islet allografts
which requires islets from two or three donor prepa-
rations. They used an immunosuppressive proto-
col comprised of induction therapy with a human-
ized interleukin-2 (IL-2) receptor antibody
(daclizumab) and maintenance therapy involving
low-dose tacrolimus and sirolimus. Later, a follow-
up in more than 50 patients treated at the Edmon-
ton site confirmed 1-year insulin independence rates
of 80%.9 From January 1990 and December 2005
(Islet Transplantation Registry, Giessen) islet
allotransplants have been performed in 1.049 pa-
tients with type I diabetes mellitus, however, there
are only 11 institutions worldwide, four in North
America and seven in Europe, to have performed
more than 20 cases per center and which have
transplanted together more than half of all cases
worldwide. Table 1.
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Future perspectives
The concept of islet cell transplantation
offers many perspectives: 1. In contrast to pan-
creas organ transplantation, islet cell aviability
could become unlimited, when strategies such
as the use of xenogenic islets, engineered beta cell
lines, in vitro stem cell expansion and differentia-
tion in insulin-producing cells or transdifferentia-
tion of non-pancreatic cells into beta cells reach
the stage of clinical applicability; 2. Islet cells may
be transplanted  without chronic immunoisupres-
sive treatment of the recipient by making use of
donor-specific tolerance induction strategies or im-
munoisolation systems. This unique set of  charac-
teristics could finally allow adolescents and chil-
dren with type I diabetes preventing devastating
diabetic secondary complications like end-stage
renal disease, lower limb ischemia, amputations
and blindness.
Cumalative 1-year graft-survival (a) and insulin independence rates (b) in 458 well-documented pre-
transplant C-peptide negative type I diabetic recipients era. Data from International Islet Transplant Registry,
Giessen, Germany.
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